PartnershipJun 9, 2026, 07:01 AM
Cartesian Therapeutics Partners with WestGene for In Vivo CAR-T Therapies
AI Summary
Cartesian Therapeutics announced a strategic licensing agreement with WestGene Biopharma to advance novel in vivo chimeric antigen receptor T-cell (CAR-T) therapies for autoimmune diseases. The partnership integrates Cartesian's mRNA payload from Descartes-08 with WestGene's targeted lipid nanoparticle (LNP) platform, aiming to eliminate ex vivo manufacturing. A Phase 1 dose-escalation study for generalized myasthenia gravis is expected to initiate in 2H 2026, with clinical data anticipated in 1H 2027. WestGene will receive an upfront payment and potential milestone payments.
Key Highlights
- Cartesian Therapeutics formed a strategic licensing agreement with WestGene Biopharma.
- Aims to develop novel in vivo CAR-T therapies for autoimmune diseases.
- Combines Cartesian's mRNA payload (from Descartes-08) with WestGene's LNP platform.
- Phase 1 clinical trial for myasthenia gravis expected to start in 2H 2026.
- Initial clinical data anticipated in 1H 2027.
- WestGene to receive upfront payment and potential development/commercial milestones.
- Cartesian plans to advance multiple anti-BCMA CAR constructs and a BCMA-directed TCE.
Price Impact
More from RNAC